Naimish Patel bought CRSP once, on Apr 3, 2025

Naimish Patel, M.D. is a biotech and pharmaceutical executive and pulmonary and critical care physician who serves as Chief Medical Officer at CRISPR Therapeutics AG (Nasdaq: CRSP), a gene-editing biopharmaceutical company focused on transformative gene-based medicines.( He joined CRISPR Therapeutics in May 2024 from Sanofi, where he most recently held the role of Global Development Therapeutic Area Head of Immunology and Inflammation, overseeing an industry‑leading pipeline across respiratory, dermatology, gastroenterology, and rheumatology, as well as key business development and M&A activities during a period of rapid portfolio expansion.( At Sanofi, he previously served as Global Program Head for Dupilumab (Dupixent), leading multiple waves of indication expansion, including chronic obstructive pulmonary disease and eosinophilic esophagitis.(

Patel is board‑certified in pulmonary and critical care medicine and has an extensive background in translational medicine and clinical trials.( He received a B.S. in Mechanical Engineering from MIT and an M.D. from McGill University, followed by internal medicine residency at Columbia‑Presbyterian Hospital and fellowship training in Pulmonary and Critical Care Medicine at Harvard Medical School.( After fellowship, he served on the faculty at Harvard and Beth Israel Deaconess Medical Center, where he led an NIH‑funded translational immunology laboratory focused on innate defense functions of the lungs.( He has also held clinical development and discovery leadership roles at AstraZeneca and Vertex Pharmaceuticals, contributing to the development of multiple blockbuster drugs and strategies for sustainable pipelines addressing diseases with high unmet medical need.( As a corporate insider at CRISPR Therapeutics AG, Patel’s executive responsibilities include guiding clinical strategy and development for the company’s gene‑based therapies.(

Written by Perplexity from public sources.